Healthcare >> CEO Interviews >> January 10, 2001

Jean-jacques Bienaime – Sangstat Medical Corporation (sang)

JEAN-JACQUES BIENAIM is Chairman, Chief Executive Officer and President of Genencor International, Inc. Mr. Bienaim joined Genencor in November 2002 from SangStat Medical Corporation where he served as Chairman, Chief Executive Officer and President. Since 1998 he managed SangStat's growth from a $4 million company to over $100 million and guided the company to profitability. A biotechnology company focused on immunology, SangStat has two drugs on the market and two more in advanced stages of clinical development. Before joining SangStat, Mr. Bienaim was Senior Vice President of Corporate Marketing and Business Development at Rhone- Poulenc Rorer Pharmaceuticals (now Aventis), a $6 billion business, where he was responsible for worldwide marketing, medical affairs strategy, licensing and business development. Prior to that position, Mr. Bienaim was Vice President and General Manager of RPR's advanced therapeutic and oncology division. Other highlights of his career include five years at Genentech where he was Director of Marketing, Cardiopulmonary Products. Mr. Bienaim is a member of the Board of Directors of Aerogen Inc. and the Fox Chase Cancer Center in Philadelphia. He received an MBA from the Wharton School at the University of Pennsylvania and an undergraduate degree in Economics from the Ecole Superieure de Commerce de Paris. Profile
TWST: Could you please give a brief overview and history of your


Mr. Bienaime: We have continued to grow since I last spoke to you

several months ago, but we have changed the